

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

(Print or Type Responses)

1. Name and Address of Reporting Person WuXi PharmTech Healthcare Fund I L.P. (Last) (First) (Middle) PO BOX 309, UGLAND HOUSE (Street) GRAND CAYMAN, E9 KYI - 1104 (City) (State) (Zip)	2. Date of Event Requiring Statement (Month/Day/Year) 06/29/2016	3. Issuer Name and Ticker or Trading Symbol Syros Pharmaceuticals, Inc. [SYRS]	
		4. Relationship of Reporting Person(s) to Issuer (Check all applicable) <input type="checkbox"/> Director <input checked="" type="checkbox"/> 10% Owner <input type="checkbox"/> Officer (give title below) <input type="checkbox"/> Other (specify below)	5. If Amendment, Date Original Filed (Month/Day/Year) 06/29/2016
		6. Individual or Joint/Group Filing (Check Applicable Line) <input checked="" type="checkbox"/> Form filed by One Reporting Person <input type="checkbox"/> Form filed by More than One Reporting Person	

Table I - Non-Derivative Securities Beneficially Owned

1. Title of Security (Instr. 4)	2. Amount of Securities Beneficially Owned (Instr. 4)	3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	4. Nature of Indirect Beneficial Ownership (Instr. 5)
---------------------------------	---	--	---

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

SEC 1473 (7-02)

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 4)	2. Date Exercisable and Expiration Date (Month/Day/Year)		3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)		4. Conversion or Exercise Price of Derivative Security	5. Ownership Form of Derivative Security: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
	Date Exercisable	Expiration Date	Title	Amount or Number of Shares			
Series B Preferred Stock	(1)	(1)	Common Stock	531,858 (2)	\$ (1)	D	

Reporting Owners

Reporting Owner Name / Address	Relationships			
	Director	10% Owner	Officer	Other
WuXi PharmTech Healthcare Fund I L.P. PO BOX 309, UGLAND HOUSE GRAND CAYMAN, E9 KYI - 1104		X		

Signatures

WuXi PharmaTech Healthcare Fund I, L.P. By: /s/ Edward Hu Name: Edward Hu Title: Director	07/06/2016
**Signature of Reporting Person	Date

Explanation of Responses:

* If the form is filed by more than one reporting person, see Instruction 5(b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

At the time of the Initial Statement of Beneficial Ownership of Securities on Form 3 filed with the Securities and Exchange Commission on June 29, 2016, the Series B Preferred Stock was convertible into Common Stock on a 3.75-for-one basis into the number of shares shown in column 3 at any time at the holder's election and automatically upon the closing of the Issuer's initial public offering without payment of further consideration. The shares had no expiration date.

- (1) This amendment to the Initial Statement of Beneficial Ownership of Securities on Form 3 filed with the Securities and Exchange Commission on June 29, 2016 (the "Original Form 3") is being filed to correct the number of shares of Common Stock into which the reporting person's holdings of Series B Preferred Stock were convertible.
- (2) The Original Form 3 overstated the number of shares of Common Stock into which the reporting person's shares of Series B Preferred Stock were convertible by 938,008 as it did not properly reflect the 3.75-for-one conversion ratio of the Series B Preferred Stock with respect to all shares of Series B Preferred Stock held by the reporting person.

